Armistice Capital adds Theravance Biopharma Inc (TBPH) to its portfolio

Theravance Biopharma Inc (TBPH) : Armistice Capital added new position in Theravance Biopharma Inc during the most recent quarter end. The investment management firm now holds 400,000 shares of Theravance Biopharma Inc which is valued at $10,784,000 , the company said in a statement filed on Aug 15, 2016 with the SEC.Theravance Biopharma Inc makes up approximately 4.85% of Armistice Capital’s portfolio.

Other Hedge Funds, Including , Manufacturers Life Insurance Company The boosted its stake in TBPH in the latest quarter, The investment management firm added 1,407 additional shares and now holds a total of 18,025 shares of Theravance Biopharma Inc which is valued at $485,954. Tower Research Capital (trc) added TBPH to its portfolio by purchasing 229 company shares during the most recent quarter which is valued at $6,174.Blackrock Advisors boosted its stake in TBPH in the latest quarter, The investment management firm added 2,886 additional shares and now holds a total of 15,919 shares of Theravance Biopharma Inc which is valued at $429,176.Boston Partners boosted its stake in TBPH in the latest quarter, The investment management firm added 3,269 additional shares and now holds a total of 95,579 shares of Theravance Biopharma Inc which is valued at $2,425,795.Dekabank Deutsche Girozentrale boosted its stake in TBPH in the latest quarter, The investment management firm added 8,200 additional shares and now holds a total of 24,500 shares of Theravance Biopharma Inc which is valued at $621,810. Theravance Biopharma Inc makes up approx 0.01% of Dekabank Deutsche Girozentrale’s portfolio.

Theravance Biopharma Inc opened for trading at $28.26 and hit $29.15 on the upside on Thursday, eventually ending the session at $28.86, with a gain of 1.76% or 0.5 points. The heightened volatility saw the trading volume jump to 2,21,527 shares. Company has a market cap of $1,381 M.

Many Wall Street Analysts have commented on Theravance Biopharma Inc. Theravance Biopharma Inc was Downgraded by BofA/Merrill to ” Underperform” on Aug 3, 2016. Guggenheim Initiated Theravance Biopharma Inc on Jun 20, 2016 to “Buy”, Price Target of the shares are set at $30.Company shares were Reiterated by Leerink Partners on Jun 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 29 from a previous price target of $26 .

Theravance Biopharma Inc. (Theravance Biopharma) is a biopharmaceutical company. The Company is engaged to create value from a diverse set of assets: an approved product; a development pipeline of mid- and late-stage assets and a productive research platform designed for long-term growth. VIBATIV (telavancin) its commercial product is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. TD-4208 is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily nebulized treatment for chronic obstructive pulmonary disease (COPD). Axelopran (TD-1211) is an investigational potential once-daily oral treatment for opioid-induced constipation (OIC). Its earlier-stage clinical assets represent approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *